drugset / Trial / NCT04264208
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Phase 2
Terminated
4 enrolled
Andrei Iagaru
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
RandomizedCrossoverOpen-labelTreatment
Summary
This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)
Timeline
- Start
- 2020-02-05
- Primary completion
- 2022-11-22
- Completion
- 2022-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 259 mbq | Intravenous |
| Subject | 68Ga-RM2 | Diagnostic / imaging agent | 140 mbq | Intravenous |